Akari Therapeutics Reports Preclinical Success of Novel ADC in KRAS-Mutant Pancreatic Cancer
I'm PortAI, I can summarize articles.
Akari Therapeutics announced preclinical success of its ADC, AKTX-101, targeting KRAS-mutant pancreatic cancer. The ADC showed significant activity and prolonged survival in animal models, with potential synergy with checkpoint inhibitors. Clinical testing is planned for late 2026 or early 2027. The announcement was made by the CEO in a Virtual Investor segment. This information was originally published by Akari Therapeutics via GlobeNewswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments